deltatrials
Completed PHASE3 INTERVENTIONAL 5-arm NCT00957684

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial.

Sponsor: Bial - Portela C S.A.

Conditions Refractory Partial Epilepsy
Interventions eslicarbazepine acetate placebo
Updated 9 times since 2017 Last updated: Mar 11, 2025 Started: Jul 31, 2004 Primary completion: Nov 30, 2005 Completion: Feb 28, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Refractory Partial Epilepsy and is currently completed. Bial - Portela C S.A. leads this study, which shows 9 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotCompleted~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 4 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE3

  2. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE3

  3. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  4. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bial - Portela C S.A.
Data source: Bial - Portela C S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations